Cargando…
Efficacy and safety of calcium polystyrene sulfonate in patients with hyperkalemia and stage 3–5 non-dialysis chronic kidney disease: a single-center randomized controlled trial
OBJECTIVE: To observe the clinical efficacy and safety of the short-term administration of different doses of calcium polystyrene sulfonate in the treatment of hyperkalemia in patients with stage 3–5 non-dialysis chronic kidney disease. METHODS: A prospective, open, randomized, controlled, single-ce...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10119845/ https://www.ncbi.nlm.nih.gov/pubmed/37063062 http://dx.doi.org/10.1177/03000605231167516 |
_version_ | 1785029081166774272 |
---|---|
author | Wang, Xia Chen, Dacheng Song, Xia Wang, Jinquan Zhang, Haitao |
author_facet | Wang, Xia Chen, Dacheng Song, Xia Wang, Jinquan Zhang, Haitao |
author_sort | Wang, Xia |
collection | PubMed |
description | OBJECTIVE: To observe the clinical efficacy and safety of the short-term administration of different doses of calcium polystyrene sulfonate in the treatment of hyperkalemia in patients with stage 3–5 non-dialysis chronic kidney disease. METHODS: A prospective, open, randomized, controlled, single-center clinical observation was conducted. In total, 107 patients were randomly assigned to receive calcium polystyrene sulfonate at 15 (group A) or 30 mg/day (group B) for 1 week. Patients were assessed on days 0, 3, and 7. RESULTS: After 3 days of treatment, the serum potassium levels in groups A and B had decreased by 0.68 ± 0.46 and 0.75 ± 0.43 mmol/L, respectively. After 7 days, the serum potassium levels in groups A and B had decreased by 0.64 ± 0.37 and 0.94 ± 0.49 mmol/L, respectively. Conversely, serum sodium, phosphorus, and calcium levels did not significantly change during the treatment period. Constipation was the most common adverse drug reaction, and no treatment-related serious adverse events were observed. CONCLUSION: Calcium polystyrene sulfonate administered at a dose of 15 or 30 g/day can rapidly reduce potassium levels in patients with stage 3–5 non-dialysis chronic kidney disease without adverse effects on sodium, phosphorus, or calcium levels. |
format | Online Article Text |
id | pubmed-10119845 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-101198452023-04-22 Efficacy and safety of calcium polystyrene sulfonate in patients with hyperkalemia and stage 3–5 non-dialysis chronic kidney disease: a single-center randomized controlled trial Wang, Xia Chen, Dacheng Song, Xia Wang, Jinquan Zhang, Haitao J Int Med Res Prospective Clinical Research Report OBJECTIVE: To observe the clinical efficacy and safety of the short-term administration of different doses of calcium polystyrene sulfonate in the treatment of hyperkalemia in patients with stage 3–5 non-dialysis chronic kidney disease. METHODS: A prospective, open, randomized, controlled, single-center clinical observation was conducted. In total, 107 patients were randomly assigned to receive calcium polystyrene sulfonate at 15 (group A) or 30 mg/day (group B) for 1 week. Patients were assessed on days 0, 3, and 7. RESULTS: After 3 days of treatment, the serum potassium levels in groups A and B had decreased by 0.68 ± 0.46 and 0.75 ± 0.43 mmol/L, respectively. After 7 days, the serum potassium levels in groups A and B had decreased by 0.64 ± 0.37 and 0.94 ± 0.49 mmol/L, respectively. Conversely, serum sodium, phosphorus, and calcium levels did not significantly change during the treatment period. Constipation was the most common adverse drug reaction, and no treatment-related serious adverse events were observed. CONCLUSION: Calcium polystyrene sulfonate administered at a dose of 15 or 30 g/day can rapidly reduce potassium levels in patients with stage 3–5 non-dialysis chronic kidney disease without adverse effects on sodium, phosphorus, or calcium levels. SAGE Publications 2023-04-16 /pmc/articles/PMC10119845/ /pubmed/37063062 http://dx.doi.org/10.1177/03000605231167516 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Prospective Clinical Research Report Wang, Xia Chen, Dacheng Song, Xia Wang, Jinquan Zhang, Haitao Efficacy and safety of calcium polystyrene sulfonate in patients with hyperkalemia and stage 3–5 non-dialysis chronic kidney disease: a single-center randomized controlled trial |
title | Efficacy and safety of calcium polystyrene sulfonate in patients with
hyperkalemia and stage 3–5 non-dialysis chronic kidney disease: a single-center
randomized controlled trial |
title_full | Efficacy and safety of calcium polystyrene sulfonate in patients with
hyperkalemia and stage 3–5 non-dialysis chronic kidney disease: a single-center
randomized controlled trial |
title_fullStr | Efficacy and safety of calcium polystyrene sulfonate in patients with
hyperkalemia and stage 3–5 non-dialysis chronic kidney disease: a single-center
randomized controlled trial |
title_full_unstemmed | Efficacy and safety of calcium polystyrene sulfonate in patients with
hyperkalemia and stage 3–5 non-dialysis chronic kidney disease: a single-center
randomized controlled trial |
title_short | Efficacy and safety of calcium polystyrene sulfonate in patients with
hyperkalemia and stage 3–5 non-dialysis chronic kidney disease: a single-center
randomized controlled trial |
title_sort | efficacy and safety of calcium polystyrene sulfonate in patients with
hyperkalemia and stage 3–5 non-dialysis chronic kidney disease: a single-center
randomized controlled trial |
topic | Prospective Clinical Research Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10119845/ https://www.ncbi.nlm.nih.gov/pubmed/37063062 http://dx.doi.org/10.1177/03000605231167516 |
work_keys_str_mv | AT wangxia efficacyandsafetyofcalciumpolystyrenesulfonateinpatientswithhyperkalemiaandstage35nondialysischronickidneydiseaseasinglecenterrandomizedcontrolledtrial AT chendacheng efficacyandsafetyofcalciumpolystyrenesulfonateinpatientswithhyperkalemiaandstage35nondialysischronickidneydiseaseasinglecenterrandomizedcontrolledtrial AT songxia efficacyandsafetyofcalciumpolystyrenesulfonateinpatientswithhyperkalemiaandstage35nondialysischronickidneydiseaseasinglecenterrandomizedcontrolledtrial AT wangjinquan efficacyandsafetyofcalciumpolystyrenesulfonateinpatientswithhyperkalemiaandstage35nondialysischronickidneydiseaseasinglecenterrandomizedcontrolledtrial AT zhanghaitao efficacyandsafetyofcalciumpolystyrenesulfonateinpatientswithhyperkalemiaandstage35nondialysischronickidneydiseaseasinglecenterrandomizedcontrolledtrial |